$ITOS
iTeos Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022016471 Filed on August 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $19.49M $41.72M $152.5M
YoY Change -81.31%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.76M $11.47M $10.62M
YoY Change 22.82% -24.04% 50.57%
% of Gross Profit
Research & Development $23.93M $26.91M $21.10M
YoY Change 48.63% 89.0% 81.19%
% of Gross Profit
Depreciation & Amortization $205.0K $195.0K $180.0K
YoY Change 16.48% 33.56% 38.46%
% of Gross Profit
Operating Expenses $34.69M $38.38M $31.71M
YoY Change 115.45% 30.82% 69.68%
Operating Profit -$15.21M $3.335M $120.8M
YoY Change -119.15% -111.37% -746.43%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $12.52M $4.669M -$2.023M
YoY Change -247.58% 7681.67% -942.92%
Pretax Income -$1.986M $8.443M $119.5M
YoY Change -102.74% -131.91% -983.21%
Income Tax -$2.977M $2.817M $49.95M
% Of Pretax Income 33.36% 41.79%
Net Earnings $1.000M $5.600M $69.58M
YoY Change -98.56% -121.16% -614.13%
Net Earnings / Revenue 5.13% 13.42% 45.62%
Basic Earnings Per Share $0.03 $0.16 $1.96
Diluted Earnings Per Share $0.03 $0.15 $1.82
COMMON SHARES
Basic Shares Outstanding 35.58M 35.55M 35.49M
Diluted Shares Outstanding 37.66M 37.64M 38.14M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $752.2M $791.9M $824.0M
YoY Change -16.4% 161.4% 156.37%
Cash & Equivalents $752.2M $791.9M $824.0M
Short-Term Investments
Other Short-Term Assets $11.74M $8.878M $12.06M
YoY Change 31.32% 241.07% 424.22%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $768.5M $804.7M $840.7M
YoY Change -15.93% 159.79% 158.74%
LONG-TERM ASSETS
Property, Plant & Equipment $2.095M $2.271M $2.216M
YoY Change -1.23% 12.37% -49.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $312.0K $320.0K $316.0K
YoY Change -23.9% -22.33% -21.0%
Total Long-Term Assets $9.327M $10.03M $9.661M
YoY Change 13.16% 12.49% 20.76%
TOTAL ASSETS
Total Short-Term Assets $768.5M $804.7M $840.7M
Total Long-Term Assets $9.327M $10.03M $9.661M
Total Assets $777.9M $814.8M $850.3M
YoY Change -15.67% 155.67% 155.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.603M $10.92M $10.60M
YoY Change 104.02% -6.35% 100.06%
Accrued Expenses $11.38M $13.81M $14.05M
YoY Change -6.65% 82.38% 164.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $93.83M $125.4M $174.3M
YoY Change -82.7% 503.93% 1376.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $25.00K $28.00K $30.00K
YoY Change -86.19% -87.83% -99.65%
Total Long-Term Liabilities $25.00K $28.00K $30.00K
YoY Change -86.19% -87.83% -99.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $93.83M $125.4M $174.3M
Total Long-Term Liabilities $25.00K $28.00K $30.00K
Total Liabilities $143.7M $177.5M $223.9M
YoY Change -73.89% 508.05% 1003.17%
SHAREHOLDERS EQUITY
Retained Earnings $216.8M $215.8M $210.2M
YoY Change -590.5% -289.46%
Common Stock $36.00K $36.00K $36.00K
YoY Change 2.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $634.2M $637.3M $626.4M
YoY Change
Total Liabilities & Shareholders Equity $777.9M $814.8M $850.3M
YoY Change -15.67% 155.67% 155.43%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income $1.000M $5.600M $69.58M
YoY Change -98.56% -121.16% -614.13%
Depreciation, Depletion And Amortization $205.0K $195.0K $180.0K
YoY Change 16.48% 33.56% 38.46%
Cash From Operating Activities -$29.70M -$30.32M -$24.00M
YoY Change -104.91% 66.1% 62.29%
INVESTING ACTIVITIES
Capital Expenditures -$105.0K -$514.0K $227.0K
YoY Change -80.26% 11.98% 157.95%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$105.0K -$514.0K -$323.0K
YoY Change -80.26% 11.98% 254.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $333.0K
YoY Change -50.07%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.000K 278.0K 333.0K
YoY Change -100.23% 44.79% -50.07%
NET CHANGE
Cash From Operating Activities -29.70M -30.32M -24.00M
Cash From Investing Activities -105.0K -514.0K -323.0K
Cash From Financing Activities -1.000K 278.0K 333.0K
Net Change In Cash -29.80M -30.56M -24.56M
YoY Change -104.93% 64.98% 64.46%
FREE CASH FLOW
Cash From Operating Activities -$29.70M -$30.32M -$24.00M
Capital Expenditures -$105.0K -$514.0K $227.0K
Free Cash Flow -$29.59M -$29.81M -$24.23M
YoY Change -104.89% 67.5% 62.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001808865
CY2022Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
12965000
CY2022Q2 us-gaap Deferred Income Current
DeferredIncomeCurrent
938000
CY2021Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
827000
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
CY2022Q2 us-gaap Deferred Revenue
DeferredRevenue
85987000
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
280225000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
778000
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
770000
dei Entity File Number
EntityFileNumber
001-39401
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
125395000
dei Entity Registrant Name
EntityRegistrantName
iTeos Therapeutics, Inc.
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
304124000
CY2022Q2 itos Grants Repayable
GrantsRepayable
5492000
CY2021Q4 itos Grants Repayable
GrantsRepayable
6164000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4029000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4571000
CY2022Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
42529000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3365066
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
17000000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4807000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
778000
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
60000
dei Entity Address Address Line1
EntityAddressAddressLine1
321 Arsenal St
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
339
dei Local Phone Number
LocalPhoneNumber
217 0161
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-837000
dei Trading Symbol
TradingSymbol
ITOS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
28000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
33000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35575323
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
791861000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
848537000
CY2022Q2 us-gaap Grants Receivable Current
GrantsReceivableCurrent
4004000
CY2021Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
4022000
CY2022Q2 itos Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
0
CY2021Q4 itos Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
524000
CY2022Q2 us-gaap Income Tax Receivable
IncomeTaxReceivable
0
CY2022Q2 us-gaap Liabilities
Liabilities
177473000
CY2021Q4 us-gaap Liabilities
Liabilities
331892000
CY2021Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
7544000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-549000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8878000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14086000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
804743000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
874713000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2271000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2072000
CY2022Q2 itos Research And Development Tax Credit Receivable Non Current
ResearchAndDevelopmentTaxCreditReceivableNonCurrent
2358000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
611000
CY2021Q4 itos Research And Development Tax Credit Receivable Non Current
ResearchAndDevelopmentTaxCreditReceivableNonCurrent
2004000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
290000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
298000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
10921000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5145000
CY2022Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
13806000
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
17157000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4792000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5329000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
320000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
296000
CY2022Q2 us-gaap Assets
Assets
814774000
CY2021Q4 us-gaap Assets
Assets
884712000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35575323
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35575323
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35466001
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26459000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
127976000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39993000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35466001
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
36000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
35000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
423743000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
413180000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2309000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1018000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
215831000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
140623000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
637301000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
552820000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
814774000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
884712000
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
41716000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
194238000
CY2022Q2 us-gaap Revenues
Revenues
41716000
us-gaap Revenues
Revenues
194238000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26910000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14238000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48006000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25881000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11471000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15101000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22086000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22147000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
38381000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
29339000
us-gaap Operating Expenses
OperatingExpenses
70092000
us-gaap Operating Expenses
OperatingExpenses
48028000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
3335000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-29339000
us-gaap Operating Income Loss
OperatingIncomeLoss
124146000
us-gaap Operating Income Loss
OperatingIncomeLoss
-48028000
CY2022Q2 itos Grant Income
GrantIncome
147000
CY2021Q2 itos Grant Income
GrantIncome
2701000
itos Grant Income
GrantIncome
638000
itos Grant Income
GrantIncome
7616000
CY2022Q2 itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
292000
CY2021Q2 itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
119000
itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
546000
itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
119000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4669000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
60000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2646000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
300000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
8443000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2817000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
52768000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
5626000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-26459000
us-gaap Net Income Loss
NetIncomeLoss
75208000
us-gaap Net Income Loss
NetIncomeLoss
-39993000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.14
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.15
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.98
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.14
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35546605
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35119952
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35520086
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35103294
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37635828
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35119952
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37931692
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35103294
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
5626000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-26459000
us-gaap Net Income Loss
NetIncomeLoss
75208000
us-gaap Net Income Loss
NetIncomeLoss
-39993000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-741000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-74000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1291000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-379000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4885000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26533000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
73917000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40372000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
323197000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2584000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
667000
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-305000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-13534000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
312609000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3227000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
195000
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-74000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-26459000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
289498000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
552820000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4193000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
333000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-550000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
69582000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
626378000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5760000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
278000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-741000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
5626000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
637301000
us-gaap Profit Loss
ProfitLoss
75208000
us-gaap Profit Loss
ProfitLoss
-39993000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
375000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
276000
us-gaap Share Based Compensation
ShareBasedCompensation
9953000
us-gaap Share Based Compensation
ShareBasedCompensation
5811000
itos Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
4000
itos Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
8000
itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-333000
itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-4185000
itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
41000
itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
-73000
itos Refundable Income Taxes
RefundableIncomeTaxes
7544000
itos Refundable Income Taxes
RefundableIncomeTaxes
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4360000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-81000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6447000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8265000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2286000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
50000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
12965000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
0
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
189000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3431000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-194238000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
itos Increase Decrease In Unrecognized Tax Benefits
IncreaseDecreaseInUnrecognizedTaxBenefits
-25529000
itos Increase Decrease In Unrecognized Tax Benefits
IncreaseDecreaseInUnrecognizedTaxBenefits
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-54324000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33045000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
738000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
489000
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
99000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
862000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
611000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
862000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2134000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-650000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-56684000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33382000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
848835000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
336454000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
792151000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
303072000
itos Capital Expenditure Included In Accounts Payable
CapitalExpenditureIncludedInAccountsPayable
-57000
itos Capital Expenditure Included In Accounts Payable
CapitalExpenditureIncludedInAccountsPayable
459000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
177000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3316000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
6740000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2021 us-gaap Net Income Loss
NetIncomeLoss
214500000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
5600000
us-gaap Net Income Loss
NetIncomeLoss
75200000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
215800000
CY2022Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
778004000
CY2022Q2 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
778004000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
797448000
CY2021Q4 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
797448000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.94
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5292000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5043000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3021000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2971000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2271000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2072000
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2022Q2 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
10963000
CY2021Q4 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
12991000
CY2022Q2 itos Accrued Personnel Costs Current
AccruedPersonnelCostsCurrent
2723000
CY2021Q4 itos Accrued Personnel Costs Current
AccruedPersonnelCostsCurrent
3884000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
27000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
25000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
93000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
257000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13806000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17157000
itos Upfront Payment Received
UpfrontPaymentReceived
625000000.0
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4029000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
280225000
itos Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
194238000
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
85987000
us-gaap Research And Development Arrangement With Federal Government Costs Incurred Net
ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet
900000
itos Percentage Of Royalty On Revenue
PercentageOfRoyaltyOnRevenue
0.30
CY2021 itos Percentage Of Royalty On Revenue
PercentageOfRoyaltyOnRevenue
0.0012
CY2022Q2 itos Proceeds Received From Grants
ProceedsReceivedFromGrants
473000
CY2022Q2 itos Grant Income
GrantIncome
147000
CY2021Q2 itos Grant Income
GrantIncome
2701000
itos Proceeds Received From Grants
ProceedsReceivedFromGrants
473000
itos Grant Income
GrantIncome
638000
itos Grant Income
GrantIncome
7616000
CY2022Q2 us-gaap Grants Receivable Current
GrantsReceivableCurrent
4004000
CY2021Q2 us-gaap Grants Receivable Current
GrantsReceivableCurrent
4022000
CY2022Q2 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
5653000
CY2021Q2 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
6164000
CY2020Q3 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holders to one vote on all matters submitted to a vote of the Company’s stockholders.
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
0.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P36M
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5760000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3227000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9953000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5811000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5207084
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.35
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1237467
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
33.79
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
26831
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.80
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
109322
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.58
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6308398
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.35
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
45432
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2649909
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.20
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M12D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
27105
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
24.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
26.56
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0196
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0307
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0084
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0090
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0137
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0307
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0042
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0090
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.86
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.93
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.94
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-22064000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-23152000
us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-37706000
us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-30204000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
30507000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-3307000
us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
165682000
us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-9789000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
8443000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26459000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
127976000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39993000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2817000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
52768000
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.334
CY2021Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.412
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.25
CY2022Q2 itos Liability For Uncertain Tax Position Current
LiabilityForUncertainTaxPositionCurrent
3200000
itos Liability For Uncertain Tax Position Current
LiabilityForUncertainTaxPositionCurrent
25500000
CY2022Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
3900000
CY2022Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
3900000
CY2022Q2 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
1577
us-gaap Other Commitments Description
OtherCommitmentsDescription
In January 2021, the Company entered into an amendment to extend the lease, effective February 2021 with a termination date of January 2030, and increase the office and laboratory space
CY2022Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
CY2021Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
600000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y4M24D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y10M24D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0478
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0476
CY2022Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2021Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
110000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
177000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3316000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
234000
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
189000
us-gaap Operating Lease Payments
OperatingLeasePayments
484000
us-gaap Operating Lease Payments
OperatingLeasePayments
374000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
503000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
999000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
982000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
952000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
924000
CY2022Q2 itos Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1197000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5557000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
750000
CY2022Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
5626000
CY2021Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-26459000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
75208000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-39993000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35546605
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35119952
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35520086
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35103294
CY2022Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2089223
CY2021Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2411606
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37635828
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35119952
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37931692
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35103294
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.14
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.15
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.98
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.14

Files In Submission

Name View Source Status
0000950170-22-016471-index-headers.html Edgar Link pending
0000950170-22-016471-index.html Edgar Link pending
0000950170-22-016471.txt Edgar Link pending
0000950170-22-016471-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
itos-20220630.htm Edgar Link pending
itos-20220630.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
itos-20220630_cal.xml Edgar Link unprocessable
itos-20220630_def.xml Edgar Link unprocessable
itos-20220630_htm.xml Edgar Link completed
itos-ex31_1.htm Edgar Link pending
itos-ex31_2.htm Edgar Link pending
itos-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
itos-20220630_pre.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
itos-20220630_lab.xml Edgar Link unprocessable